Discover Oncology, Journal Year: 2025, Volume and Issue: 16(1)
Published: March 29, 2025
Bladder urothelial carcinoma (BUC) is a common malignant tumour with high recurrence rate and mortality. Research on the molecular pathological basis of BUC extensive. However, specific pathogenesis effective treatment remain to be further studied. Studies mutation spectrum, DNA methylation, non-coding RNA, proliferation apoptosis signalling pathways, cell cycle control, transcription factors, damage repair, immune checkpoint microenvironment have provided therapeutic strategies for diagnosis, prognosis evaluation BUC. This study new insights into pathology BUC, helped improve prognostic patients drove use precision medicine in
Language: Английский
Citations
0Intratumoral Heterogeneity of Molecular Subtypes in Muscle-invasive Bladder Cancer—An Extensive Multiregional Immunohistochemical Analysis
European Urology Focus, Journal Year: 2023, Volume and Issue: 9(5), P. 788 - 798
Published: April 17, 2023
Language: Английский
Citations
9Immunohistochemical Study of Bladder Cancer Molecular Subtypes and Their Association with PD-L1 Expression
Cancers, Journal Year: 2022, Volume and Issue: 15(1), P. 188 - 188
Published: Dec. 28, 2022
The significant heterogeneity in clinical outcomes among patients with bladder cancer has highlighted the existence of different biological subtypes muscle-invasive (MIBC) and non-muscle-invasive (NMIBC). Meanwhile, immune checkpoint proteins their interference tumor-related immune-evasive strategies led to development several immunotherapeutic drugs targeting programmed death-1 (PD-1) or death ligand-1 (PD-L1). However, lack any known biomarker that could predict responses immunotherapy a more agnostic therapeutic approach. Here, we present study conducted 77 (BC) (n = 77), ranging from stages pTa pT2. Tumor specimens were resected via transurethral resection tumor (TURBT) consistuted 24 low-grade (LG) 53 high-grade (HG) tumors. Patients’ tumors then categorized into molecular subtypes, immunohistochemistry (CK5/6 GATA3). Furthermore, all stained anti-PD-L1 demonstrated correlations basal immunophenotype, stage pT2 HG As such, attempted stratify groups likely-responders likely-not-responders anti-PD-L1, based on phenotype. Finally, acknowledging fact there is universal biomarkers associated predicting BC response drugs, tested for deficiency mismatch repair (MMR).
Language: Английский
Citations
8Molecular classification of muscle-invasive bladder cancer based on a simplified immunohistochemical panel using GATA3, CK5/6 and p16
Biomolecules and Biomedicine, Journal Year: 2023, Volume and Issue: unknown
Published: June 21, 2023
The choice of therapy for muscle-invasive bladder cancer (MIBC) could be influenced by the tumor’s molecular subtype. Currently, well-defined consensus subtypes are based on tumor microarray mRNA data. Clearly defined and easy-to-use surrogate subtypes, immunohistochemistry (IHC) performed whole slides, needed to make subtyping cost-effective useful in routine work future research. To aid development a simple immunohistochemical classifier, retrospective single-center series 92 cases localized was identified. Routine IHC GATA3, cytokeratins 5 6 (CK5/6), p16 tissue blocks containing disease. Electronic medical records were retrieved searched clinical variables, treatment, survival mean age 69.6 years, 73% males. Conservative treatment used 55% cases, while cystectomy with chemotherapy 45%. GATA3 CK5/6 expression divided into broad luminal basal respectively, subclassify papillary unstable types according classification. When subtyped this way, negative showed worse overall survival. Molecular MIBC slides using only three commonly used, consensus-based antibodies, is feasible method detecting invasive cancer. Future combining morphological analysis fully translate classification comprehensive, strategy.
Language: Английский
Citations
4The Role of Immunohistochemistry as a Surrogate Marker in Molecular Subtyping and Classification of Bladder Cancer
Diagnostics, Journal Year: 2024, Volume and Issue: 14(22), P. 2501 - 2501
Published: Nov. 8, 2024
Bladder cancer (BC) is a highly heterogeneous disease, presenting clinical challenges, particularly in predicting patient outcomes and selecting effective treatments. Molecular subtyping has emerged as an essential tool for understanding the biological diversity of BC; however, its implementation practice remains limited due to high costs complexity genomic techniques. This review examines role immunohistochemistry (IHC) surrogate marker molecular BC, highlighting potential bridge gap between advanced classifications routine application; Methods: We explore evolution taxonomic classification with particular focus on cytokeratin (KRT) expression patterns normal urothelium, which are key identifying basal luminal subtypes. Furthermore, we emphasise need consensus IHC markers reliably define these subtypes, facilitating wider standardised use. The also analyses application both muscle-invasive (MIBC) non-muscle-invasive bladder (NMIBC), attention less extensively studied NMIBC cases. discuss practical advantages subtyping, including cost effectiveness feasibility standard pathology laboratories, alongside ongoing challenges such requirement protocols external validation across diverse settings; Conclusions: While limitations, it offers viable alternative laboratories lacking access Further research required determine optimal combination markers, establish diagnostic algorithm, validate through large-scale trials. will ultimately enhance accuracy, guide treatment decisions, improve outcomes.
Language: Английский
Citations
1Development of a Clinically Applicable NanoString-Based Gene Expression Classifier for Muscle-Invasive Bladder Cancer Molecular Stratification
Cancers, Journal Year: 2022, Volume and Issue: 14(19), P. 4911 - 4911
Published: Oct. 7, 2022
Transcriptional profiling of muscle-invasive bladder cancer (MIBC) using RNA sequencing (RNA-seq) technology has demonstrated the existence intrinsic basal and luminal molecular subtypes that vary in their prognosis response to therapy. However, routine use RNA-seq a clinical setting is restricted by cost technical difficulties. Herein, we provide single-sample NanoString-based seven-gene (KRT5, KRT6C, SERPINB13, UPK1A, UPK2, UPK3A KRT20) MIBC classifier assigns subtype. The was developed series 138 chemotherapy naïve MIBCs split into training (70%) testing (30%) datasets. Further, validated previously published CK5/6 GATA3 immunohistochemical which showed high concordance 96.9% with gene expression classifier. Immunohistochemistry-based significantly correlated recurrence-free survival (RFS) disease-specific (DSS) univariable (p = 0.006 p 0.011, respectively) multivariate cox regression analysis for DSS 0.032). Used sequentially, immunohistochemical- classifiers faster turnaround time, lower per sample simpler data ease implementation diagnostics.
Language: Английский
Citations
4Scoring Systems for Immunohistochemistry in Urothelial Carcinoma
Methods in molecular biology, Journal Year: 2023, Volume and Issue: unknown, P. 3 - 25
Published: Jan. 1, 2023
Language: Английский
Citations
1P16 Expression in Grading of Urothelial Carcinoma
Journal of Saidu Medical College Swat, Journal Year: 2023, Volume and Issue: 13(4), P. 180 - 185
Published: Dec. 19, 2023
Background: Sleep is one of the most important determinants human health. The quality sleep has significant effects on academic performance and influenced by multiple factors.Objectives: To determine association between patterns / Quality dental undergraduates during their summative clinical examination using an objective measure.Material Methods: This descriptive cross-sectional study was conducted at Department Medicine, Khyber Teaching Hospital Peshawar, from February 1, 2023, to June 30, 2023. A sample size 82 calculated Open Epi calculator. validated questionnaire Pittsburgh Index (PSQI) used in this study. participants were selected convenience based consecutive sampling technique 3rd BDS Students appearing annual General Medicine Examination. After data collection, these variables analyzed SPSS version 26 software.Results: comprised 43(52.4%) female 39(47.6%) male participants, amongst them, 34.1% females 20.7% males rendered bad, whereas 18.3% 26.8% responded otherwise. findings positively associated with bad (47.6%). Measures significantly deranged among poor sleepers compared normal sleepers. On average, poor-quality good good-quality Still, finding not statistically significant, as evidenced t-test (Mean 574 ± SD 62.156 vs. 581 79.769) p-value 0.640.Conclusion: Poor common our students. students comparison that Keywords: Academic performance, Dental undergraduates, PSQI,
Language: Английский
Citations
1Co‑occurrence of clear cell renal cell carcinoma and bladder urothelial carcinoma: A case report and literature review
Oncology Letters, Journal Year: 2024, Volume and Issue: 29(1)
Published: Oct. 23, 2024
The co-occurrence of clear cell renal carcinoma (ccRCC) and bladder urothelial (bUC) is rare, owing to the lack a unified treatment plan, prognosis poor. present report describes case 65-year-old male patient with history smoking no malignant tumors who presented hematuria at Huanghe Sanmenxia Hospital Affiliated Henan University Science Technology (Sanmenxia, China) in July 2021. Urinary system computed tomography urography revealed right tumor, cystoscopy intravesical lesions. underwent transurethral resection tumor + laparoscopic partial nephrectomy radical cystectomy bilateral ureterostomy. Pathological examination right-sided ccRCC (pT1aN0M0) high-grade invasive bUC (pT2N0M0). After surgery, ureteral single J tube replacement outpatient clinic every 3 months. In September 2022, mass on side neck. Further space-occupying lesion lower part left kidney lesions neck, axilla, mediastinal lymph nodes liver. A neck node puncture biopsy suggested UC, was diagnosed metastatic UC (T4N0M1). received tislelizumab (200 mg once weeks) sunitinib (50 mg/day, administered for 4 weeks 2-week interval) total 2 months died an advanced January 2023. addition, data 36 patients from literature were analyzed report. results showed that median age first onset 56.5 years (range, 31-82 years) male-to-female ratio 6:1. Smoking sex may be risk factors this disease, which has survival time 47.5 analysis pathological stage cancer associated its prognosis. study reviews potential risks, clinicopathological characteristics methods bUC. conclusion, high-risk sex, related
Language: Английский
Citations
0The pitfalls of an invasive non-neuroendocrine GATA3- and TTF1+ urothelial carcinoma
Pathologica, Journal Year: 2024, Volume and Issue: 116(5), P. 335 - 337
Published: Oct. 1, 2024
Language: Английский
Citations
0